Education
About Us
Working with TipRanks
Follow Us
Captor Therapeutics SA (DE:60Q)
STUTTGART:60Q
60Q Stock Chart & Stats
€9.02
-€0.22(-2.21%)
At close: 4:00 PM EST
€9.02
-€0.22(-2.21%)
Day’s Range― - ―
52-Week Range€6.96 - €20.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€109.45M
Enterprise Value€450.50M
Total Cash (Recent Filing)€35.97M
Total Debt (Recent Filing)€3.82M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Apr 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding5,553,397
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.06
Price to Sales (P/S)12.45
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
60Q FAQ
What was Captor Therapeutics SA’s price range in the past 12 months?
Captor Therapeutics SA lowest stock price was €6.96 and its highest was €20.20 in the past 12 months.
What is Captor Therapeutics SA’s market cap?
Captor Therapeutics SA’s market cap is €109.45M.
When is Captor Therapeutics SA’s upcoming earnings report date?
Captor Therapeutics SA’s upcoming earnings report date is Apr 02, 2026 which is in 47 days.
How were Captor Therapeutics SA’s earnings last quarter?
Captor Therapeutics SA released its earnings results on Nov 20, 2025. The company reported -€0.493 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.493.
Is Captor Therapeutics SA overvalued?
According to Wall Street analysts Captor Therapeutics SA’s price is currently Overvalued.
Does Captor Therapeutics SA pay dividends?
Captor Therapeutics SA does not currently pay dividends.
What is Captor Therapeutics SA’s EPS estimate?
Captor Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Captor Therapeutics SA have?
Captor Therapeutics SA has 5,553,397 shares outstanding.
What happened to Captor Therapeutics SA’s price movement after its last earnings report?
Captor Therapeutics SA reported an EPS of -€0.493 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.866%.
Which hedge fund is a major shareholder of Captor Therapeutics SA?
Currently, no hedge funds are holding shares in DE:60Q
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Captor Therapeutics SA
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.
Technical Analysis
Pure Biologics SA
―
Ryvu Therapeutics SA
―
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
―
OncoArendi Therapeutics SA
―
Selvita SA
―
Options Prices
Currently, No data available
---